Physiopathology of Pulmonary Hypertension: from Bio-Molecular Mechanism to Target TreatmentDuong-Quy S1,2*
- *Corresponding Author:
- Sy Duong-Quy
MD, PhD, Department of Cardio-Respiratory Diseases
Cochin Hospital, Paris Descartes University, France and
Department of Medicine, Penn State Medical College, USA
E-mail: [email protected]
Received Date: November 30, 2016; Accepted Date: December 22, 2016; Published Date: December 29, 2016
Citation: Duong-Quy S (2016) Physiopathology of Pulmonary Hypertension: from Bio-Molecular Mechanism to Target Treatment. J Vasc Med Surg 4:294. doi: 10.4172/2329-6925.1000294
Copyright: © 2016 Duong-Quy S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Although the diagnosis and treatment of pulmonary hypertension (PH) is developed constantly in the last decade, PH remains an incurable and difficult to treat disease due to its high life disability and dreadful survival rate. The disease is characterized by sustained vasoconstriction, progressive vascular remodeling, and irreversible right heart dysfunction. The advanced knowledge in physiopathology and classification of PH in recent years is a useful tool helping physicians to improve the choice of target treatment. In addition, the remarkable progresses in understanding the molecular and cellular mechanisms of PH allow to develop new treatments. Actually, new therapeutic molecules have been discovered and their mechanisms of action are better understood and some are in preclinical and clinical trials. Preliminary results of these molecules with benefit effects on pulmonary arterial pressure and systemic hemodynamic gives a new hope for the future.